Free Trial
NASDAQ:SWKH

SWK Q2 2025 Earnings Report

SWK logo
$14.72 +0.02 (+0.14%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$14.72 +0.00 (+0.03%)
As of 08/14/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Upcoming Event
Earnings Conference Call
SWK Q2 2025
00:00 / 00:00
Live Transcript
Follow Audio

SWK EPS Results

Actual EPS
$0.38
Consensus EPS
$0.18
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

SWK Revenue Results

Actual Revenue
$10.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SWK Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Friday, August 15, 2025
Conference Call Time
10:00AM ET

SWK Earnings Headlines

7SWKH : Insights into SWK Holdings's Upcoming Earnings
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
SWKH - SWK Holdings Corp Ownership | Morningstar
See More SWK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SWK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SWK and other key companies, straight to your email.

About SWK

SWK (NASDAQ:SWKH) Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.

View SWK Profile

More Earnings Resources from MarketBeat